A Decade of Diligence: Medlab Group’s Pursuit of Better Medicine

In a world where medicine often comes with trade-offs—efficacy versus side effects, relief versus dependency—Medlab Group has quietly and persistently carved a different path. For over a decade, their mission has been clear: to make medicines not just more effective, but more humane. To improve quality of life, not just manage symptoms.

At the heart of this journey is NanoCelle®, a proprietary delivery platform that Medlab began developing more than ten years ago. The idea was simple but revolutionary: what if medicine could bypass the digestive system and deliver active ingredients directly into the bloodstream through the cheek or nasal cavity? This would mean faster absorption, lower doses, and fewer side effects.

NanoCelle is a nano-particle delivery system, designed to carry pharmaceutical and nutraceutical compounds in a way that’s both efficient and gentle. It’s a technology born from compassion—engineered not just for performance, but for the people who rely on it.

Building on NanoCelle’s success, they turned their attention to one of the most pressing challenges in healthcare: pain management. The result was NanaBis®, a cannabinoid-based formulation delivered via NanoCelle. Over several years, NanaBis has been studied across more than 1,000 patient datapoints, including real-world observational studies and clinical trials.

The findings have been encouraging. NanaBis has shown potential in managing chronic and cancer-related pain, with data suggesting reduced reliance on opioids, improved patient quality of life, and has been well tolerated. For many patients, it’s not just about pain relief—it’s about reclaiming moments of life that pain had stolen.

As they continue to develop NanaBis globally and explore new applications for NanoCelle, Medlab remains grounded in its original vision: to make medicine that heals without harm, and to do so with integrity, empathy, and scientific rigor.